BaroniSSSantilloMBevilacquaFStimulatory autoantibodies to the PDGF receptor in systemic sclerosisN Engl J Med2006354252667–7610.1056/NEJMoa052955
2.
BlakeDRWinyardPScottDGBrailsfordSBlannALunecJEndothelial cell cytotoxicity in inflammatory vascular diseases—the possible role of oxidised lipoproteinsAnn Rheum Dis.1985443176–8210.1136/ard.44.3.176
3.
BourosDWellsAUNicholsonAGColbyTVPolychronopoulosVPantelidisPHistopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcomeAm J Respir Crit Care Med20021651581–610.1164/rccm.2106012
4.
ChizzoliniCRaschiERezzonicoRAutoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosisArthritis Rheum20024661602–1310.1002/art.10361
5.
ClassenJFHenrohnDRorsmanFLennartssonJLauwerysBRWikströmGRorsmanCLenglezSFranck-LarssonKTomasiJPKämpeOVanthuyneMHoussiauFADemoulinJBLack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosisArthritis Rheum20096041137–4410.1002/art.24381
6.
DanielsCEWilkesMCEdensMImatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosisJ Clin Invest200411491308–16
7.
DiotEBoissinotEAsquierERelationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosisChest199811461623–910.1378/chest.114.6.1623
8.
GohNSVeeraraghavanSDesaiSRBronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progressionArthritis Rheum20075662005–1210.1002/art.22696
9.
HenaultJTremblayMClementIRaymondYSenecalJLDirect binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosisArthritis Rheum200450103265–7410.1002/art.20515
10.
HoylesRKEllisRWWellsburyJA multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaArthritis Rheum200654123962–7010.1002/art.22204
11.
HsuVMMoreyraAEWilsonACAssessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right—heart catheterizationJ Rheumatol2008353458–65
12.
KirouKAMavraganiCPCrowMKActivation of type I interferon in systemic lupus erythematosusExpert Rev Clin Immunol200734579–8810.1586/1744666X.3.4.579
MavaliaCScalettiCRomagnaniPType 2 helper T-cell predominance and high CD30 expression in systemic sclerosisAm J Pathol199715161751–8
15.
PandeyJPLeRoyECHuman cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosisArthritis Rheum199841110–510.1002/1529-0131(199801)41:1<10::AID-ART2>3.0.CO;2-P
16.
PannuJTrojanowskaMRecent advances in fibroblast signaling and biology in sclerodermaCurr Opin Rheumatol2004166739–4510.1097/01.bor.0000137894.63091.1a
17.
RamirezFTanakaSBou-GhariosGTranscriptional regulation of the human alpha2 (I) collagen gene (COL1A2), an informative model system to study fibrotic diseasesMatrix Biol2006256365–7210.1016/j.matbio.2006.05.002
18.
SahharJLittlejohnGConronMFibrosing alveolitis in systemic sclerosis: the need for early screening and treatmentIntern Med J20043411626–3810.1111/j.1445-5994.2004.00674.x
19.
SatoSAbnormalities of adhesion molecules and chemokines in sclerodermaCurr Opin Rheumatol1999116503–710.1097/00002281-199911000-00011
20.
SteenVDMedsgerTAChanges in causes of death in systemic sclerosis, 1972–2002Ann Rheum Dis2007667940–410.1136/ard.2006.066068
21.
TanFKZhouXMayesMDSignatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patientsRheumatology (Oxford)2006456694–70210.1093/rheumatology/kei244
22.
TashkinDPElashoffRClementsPJCyclophosphamide versus placebo in scleroderma lung diseaseN Engl J Med2006354252655–6610.1056/NEJMoa055120
23.
TashkinDPElashoffRClementsPJEffects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseAm J Respir Crit Care Med2007176101026–3410.1164/rccm.200702-326OC
24.
VargaJAbrahamDSystemic sclerosis: a prototypic multisystem fibrotic disorderJ Clin Invest20071173557–6710.1172/JCI31139
